Foresight in medicine: Current challenges with Haemophilus influenzae type b conjugate vaccines

Journal of Internal Medicine

Volumn 267, Issue 3, 2010, Pages 241-250

  Eskola, J ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Hib infections; Vaccines

Indexed keywords

DIPHTHERIA HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA TOXOID CRM197; DIPHTHERIA TOXOID CRM197 HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA VACCINE; HAEMOPHILUS INFLUENZAE TYPE B MENINGOCOCCAL OUTER MEMBRANE PROTEIN VACCINE; HAEMOPHILUS INFLUENZAE TYPE B TETANUS TOXOID VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MENINGOCOCCUS VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ADULT; CASE REPORT; CHILD; CHILDHOOD MORTALITY; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; HAEMOPHILUS MENINGITIS; HEALTH CARE COST; HEALTH PROGRAM; HEALTH PROMOTION; HUMAN; IMMUNIZATION; INFLUENZA; KNOWLEDGE; MULTICENTER STUDY; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; REVIEW;

BACTERIAL CAPSULES; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INFANT, NEWBORN; MENINGITIS, HAEMOPHILUS; VACCINES, CONJUGATE; WORLD HEALTH;

EID: 75749121835     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2009.02182.x     Document Type: Review

References (49)

1. O'Loughlin RE, Hajjeh R. Accelerating Haemophilus influenzae type b vaccine introduction in the world's poorest countries: a dream is coming true. Future Microbiol 2008 3 : 377 378.
2. Peltola H, Käyhty H, Virtanen M, Mäkelä PH. Prevention of Haemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine. N Engl J Med 1984 310 : 1561 1566.
3. Black SB, Shinefield HR, Lampert D et al. Safety and immunogenicity of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in infancy. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. Pediatr Infect Dis J 1991 10 : 92 6.
4. Eskola JKH, Peltola H. Antibody levels achieved in infants by course of Haemophilus influenzae type b polysaccharide/diphtheria toxoid conjugate vaccine. Lancet 1985 i : 1184 1186.
5. Kurikka S, Kayhty H, Peltola H, Saarinen L, Eskola J, Makela PH. Neonatal immunization: response to Haemophilus influenzae type b-tetanus toxoid conjugate vaccine. Pediatrics 1995 95 : 815 822.
6. Capeding MR, Nohynek H, Pascual LG et al. The immunogenicity of three Haemophilus influenzae type B conjugate vaccines after a primary vaccination series in Philippine infants. Am J Trop Med Hyg 1996 55 : 516 520.
7. Kayhty H, Karanko V, Peltola H, Makela PH. Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization: no evidence of immunologic tolerance or memory. Pediatrics 1984 74 : 857 865.
8. Obonyo CO, Lau J. Efficacy of Haemophilus influenzae type b vaccination of children: a meta-analysis. Eur J Clin Microbiol Infect Dis 2006 25 : 90 7.
9. Black SB, Shinefield HR, Fireman B, Hiatt R, Polen M, Vittinghoff E. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. Pediatr Infect Dis J 1991 10 : 97 104.
10. Booy R, Hodgson S, Carpenter L et al. Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T. Lancet 1994 344 : 362 366.
11. Eskola J, Kayhty H, Takala AK et al. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. N Engl J Med 1990 323 : 1381 1387.
12. Lagos R, Horwitz I, Toro J et al. Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections. Pediatr Infect Dis J 1996 15 : 216 222.
13. Mulholland K, Hilton S, Adegbola R et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants. Lancet 1997 349 : 1191 1197. (Pubitemid 27190041)
14. Santosham M, Wolff M, Reid R et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med 1991 324 : 1767 1772.
15. Ward J, Brenneman G, Letson GW, Heyward WL. Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. The Alaska H. influenzae Vaccine Study Group. N Engl J Med 1990 323 : 1393 1401.
16. Gessner BD, Adegbola RA. The impact of vaccines on pneumonia: key lessons from Haemophilus influenzae type b conjugate vaccines. Vaccine 2008 26 (Suppl 2 B3 8.
17. Adegbola RA, Mulholland EK, Secka O, Jaffar S, Greenwood BM. Vaccination with a Haemophilus influenzae type b conjugate vaccine reduces oropharyngeal carriage of H. influenzae type b among Gambian children. J Infect Dis 1998 177 : 1758 1761. (Pubitemid 28243612)
18. Takala AK, Eskola J, Leinonen M et al. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. J Infect Dis 1991 164 : 982 986.
19. Moulton LH, Chung S, Croll J, Reid R, Weatherholtz RC, Santosham M. Estimation of the indirect effect of Haemophilus influenzae type b conjugate vaccine in an American Indian population. Int J Epidemiol 2000 29 : 753 756.
20. Adams WG, Deaver KA, Cochi SL et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 1993 269 : 221 226.
21. Adegbola RA, Secka O, Lahai G et al. Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet 2005 366 : 144 150.
22. McVernon J, Ramsay ME, McLean AR. Understanding the impact of Hib conjugate vaccine on transmission, immunity and disease in the United Kingdom. Epidemiol Infect 2008 136 : 800 812.
23. Heath PT, McVernon J. The UK Hib vaccine experience. Arch Dis Child 2002 86 : 396 399.
24. Brenneman G, Silimperi D, Ward J. Recurrent invasive Haemophilus influenzae type b disease in Alaskan Natives. Pediatr Infect Dis J 1987 6 : 388 392. (Pubitemid 17070046)
25. Baqui AH, El Arifeen S, Saha SK et al. Effectiveness of Haemophilus influenzae type B conjugate vaccine on prevention of pneumonia and meningitis in Bangladeshi children: a case-control study. Pediatr Infect Dis J 2007 26 : 565 571.
26. Gessner BD, Sedyaningsih ER, Griffiths UK et al. Vaccine-preventable Haemophilus influenza type b disease burden and cost-effectiveness of infant vaccination in Indonesia. Pediatr Infect Dis J 2008 27 : 438 443.
27. Gessner BD, Sutanto A, Linehan M et al. Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe trial. Lancet 2005 365 : 43 52.
28. Brinsmead R, Hill S, Walker D. Are economic evaluations of vaccines useful to decision-makers? Case study of Haemophilus influenzae type b vaccines Pediatr Infect Dis J 2004 23 : 32 7.
29. Akumu AO, English M, Scott JA, Griffiths UK. Economic evaluation of delivering Haemophilus influenzae type b vaccine in routine immunization services in Kenya. Bull World Health Organ 2007 85 : 511 518.
30. Gessner BD. Haemophilus influenzae type b vaccine impact in resource-poor settings in Asia and Africa. Expert Review of Vaccines 2009 8 : 91 102.
31. Broughton EI. Economic evaluation of Haemophilus influenzae type B vaccination in Indonesia: a cost-effectiveness analysis. J Public Health (Oxf) 2007 29 : 441 448.
32. Lagos R, Valenzuela MT, Levine OS et al. Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunogenicity of fractional-dose and two-dose regimens. Lancet 1998 351 : 1472 1476.
33. Eskola J, Olander RM, Hovi T, Litmanen L, Peltola S, Kayhty H. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet 1996 348 : 1688 1692.
34. Dagan R, Eskola J, Leclerc C, Leroy O. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect Immun 1998 66 : 2093 2098.
35. Dagan R, Goldblatt D, Maleckar JR, Yaich M, Eskola J. Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components. Infect Immun 2004 72 : 5383 5391.
36. Parkkali T, Kayhty H, Hovi T et al. A randomized study on donor immunization with tetanus-diphtheria, Haemophilus influenzae type b and inactivated poliovirus vaccines to improve the recipient responses to the same vaccines after allogeneic bone marrow transplantation. Bone Marrow Transplant 2007 39 : 179 188.
37. Parkkali T, Kayhty H, Ruutu T, Volin L, Eskola J, Ruutu P. A comparison of early and late vaccination with Haemophilus influenzae type b conjugate and pneumococcal polysaccharide vaccines after allogeneic BMT. Bone Marrow Transplant 1996 18 : 961 967.
38. Sinsalo M, Aittoniemi J, Kayhty H, Vilpo J. Haemophilus influenzae type b (Hib) antibody concentrations and vaccination responses in patients with chronic lymphocytic leukaemia: predicting factors for response. Leuk Lymphoma 2002 43 : 1967 1969.
39. Vance E, George S, Guinan EC et al. Comparison of multiple immunization schedules for Haemophilus influenzae type b-conjugate and tetanus toxoid vaccines following bone marrow transplantation. Bone Marrow Transplant 1998 22 : 735 741.
40. Heath PT, Booy R, McVernon J et al. Hib vaccination in infants born prematurely. Arch Dis Child 2003 88 : 206 210.
41. Claesson BA, Trollfors B, Lagergard T, Knutsson N, Schneerson R, Robbins JB. Antibodies against Haemophilus influenzae type b capsular polysaccharide and tetanus toxoid before and after a booster dose of the carrier protein nine years after primary vaccination with a protein conjugate vaccine. Pediatr Infect Dis J 2005 24 : 463 464.
42. Mäkelä PH, Käyhty H, Leino T et al. Long-term persistence of immunity after immunisation with Haemophilus influenzae type b conjugate vaccine. Vaccine 2003 22 : 287 292.
43. Trotter CL, McVernon J, Ramsay ME et al. Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. Vaccine 2008 26 : 4434 4445.
44. Watt JP, Levine OS, Santosham M. Global reduction of Hib disease: what are the next steps? Proceedings of the meeting Scottsdale, Arizona, September 22-25, 2002. J Pediatr 2003 143 : S163 87.
45. Lipsitch M. Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerg Infect Dis 1999 5 : 336 345.
46. WHO. Haemophilus influenzae Type b (Hib): conclusions and recommendations from the Immunization Strategic Advisory Group. Wkly Epidemiol Rec 2006 81 : 1 12.
47. Mitchell V, Walker D, Zuber P, Lydon P, Ahun M. Evidenced-based decision making about Hib vaccination. Lancet 2005 365 : 936 937.
48. Morris SK, Moss WJ, Halsey N. Haemophilus influenzae type b conjugate vaccine use and effectiveness. Lancet Infect Dis 2008 8 : 435 443.
49. O'Loughlin R, Hajjeh R. Worldwide introduction and coverage of Haemophilus influenzae type b conjugate vaccine. Lancet Infect Dis 2008 8 : 736.